These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 10432563)

  • 1. [Decrease in the platelet level of 43 kDa immunoreactive fraction of serotonin transporting protein correlates with depressive symptoms in patients with somatoform disorders].
    Belous AR; Ramamoothy S; Blakely RD; Faktor MI; Lozier RKh; Dupin AM; Bechiashvili AG; Morozova MA; Brusov OS
    Vopr Med Khim; 1999; 45(3):256-62. PubMed ID: 10432563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The status of serotonin protein -- a serotonin transporter in thrombocytes in patients with somatoform disorders].
    Belous AR; Rammamoorthy S; Blakely RD; Factor MI; Dupin AM; Katasonov AB; Lozier RKh; Beniashvili AG; Morozova MA; Brusov OS
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(11):32-5. PubMed ID: 10578533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The state of the serotonin transporter protein in the platelets of patients with somatoform [correction of somatiform] disorders.
    Belous AR; Ramamoorthy S; Blakely RD; Factor MI; Dupin AM; Katasonov AB; Lozier RH; Beniashvili AG; Morozova MA; Brusov OS
    Neurosci Behav Physiol; 2001; 31(2):185-9. PubMed ID: 11392354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Levels and molecular heterogeneity of serotonin transporter protein in platelets of patients with different mental diseases: a comparative analysis with the use of monoclonal and polyclonal antibodies].
    Brusov OS; Faktor MI; Zlobina GP; Bologov PV; Kaleda VG; Oleĭchik IV; Korenev AN; Piatnitskiĭ AN; Dupin AM; Katasonov AB; Morozova MA; Beniashvili AG; Lozier RKh; Pavlova EV; Segal OL; Massino IuS; Dmitriev AD
    Vestn Ross Akad Med Nauk; 2001; (7):37-42. PubMed ID: 11523428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Western blot analysis of human and rat serotonin transporter in platelets and brain using site-specific antibodies: evidence that transporter undergoes endoproteolytic cleavage.
    Dmitriev AD; Factor MI; Segal OL; Pavlova EV; Massino YS; Smirnova MB; Yakovleva DA; Dmitriev DA; Kizim EA; Kolyaskina GI; Brusov OS
    Clin Chim Acta; 2005 Jun; 356(1-2):76-94. PubMed ID: 15936305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron.
    Bellini M; Rappelli L; Blandizzi C; Costa F; Stasi C; Colucci R; Giannaccini G; Marazziti D; Betti L; Baroni S; Mumolo MG; Marchi S; Del Tacca M
    Am J Gastroenterol; 2003 Dec; 98(12):2705-11. PubMed ID: 14687821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The serotonin transporter in depressed patients: a qualitative study based on dissociation kinetics.
    Mellerup ET; Bolwig TG; Dam H; Plenge P
    Biol Psychiatry; 1995 Nov; 38(10):699-700. PubMed ID: 8555384
    [No Abstract]   [Full Text] [Related]  

  • 8. Evidence for biphasic effects of protein kinase C on serotonin transporter function, endocytosis, and phosphorylation.
    Jayanthi LD; Samuvel DJ; Blakely RD; Ramamoorthy S
    Mol Pharmacol; 2005 Jun; 67(6):2077-87. PubMed ID: 15774771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of mirtazapine treatment on serotonin transporter in blood peripheral lymphocytes of major depression patients.
    Peña S; Baccichet E; Urbina M; Carreira I; Lima L
    Int Immunopharmacol; 2005 Jun; 5(6):1069-76. PubMed ID: 15829422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission.
    Vevera J; Fisar Z; Kvasnicka T; Zdenek H; Stárková L; Ceska R; Papezová H
    Psychiatry Res; 2005 Feb; 133(2-3):197-203. PubMed ID: 15740995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced hippocampal volumes associated with the long variant of the serotonin transporter polymorphism in major depression.
    Frodl T; Meisenzahl EM; Zill P; Baghai T; Rujescu D; Leinsinger G; Bottlender R; Schüle C; Zwanzger P; Engel RR; Rupprecht R; Bondy B; Reiser M; Möller HJ
    Arch Gen Psychiatry; 2004 Feb; 61(2):177-83. PubMed ID: 14757594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the relationship between serotonin and brain-derived neurotrophic factor: analysis of BDNF protein and extraneuronal 5-HT in mice with reduced serotonin transporter or BDNF expression.
    Szapacs ME; Mathews TA; Tessarollo L; Ernest Lyons W; Mamounas LA; Andrews AM
    J Neurosci Methods; 2004 Dec; 140(1-2):81-92. PubMed ID: 15589338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3,4-methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein.
    Wang X; Baumann MH; Xu H; Rothman RB
    Synapse; 2004 Sep; 53(4):240-8. PubMed ID: 15266556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenosine receptor, protein kinase G, and p38 mitogen-activated protein kinase-dependent up-regulation of serotonin transporters involves both transporter trafficking and activation.
    Zhu CB; Hewlett WA; Feoktistov I; Biaggioni I; Blakely RD
    Mol Pharmacol; 2004 Jun; 65(6):1462-74. PubMed ID: 15155839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrain.
    Rothman RB; Jayanthi S; Wang X; Dersch CM; Cadet JL; Prisinzano T; Rice KC; Baumann MH
    Synapse; 2003 Dec; 50(3):233-9. PubMed ID: 14515341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between a serotonin transporter promoter region polymorphism and mood response during tryptophan depletion.
    Moreno FA; Rowe DC; Kaiser B; Chase D; Michaels T; Gelernter J; Delgado PL
    Mol Psychiatry; 2002; 7(2):213-6. PubMed ID: 11840315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium-dependent inhibition of synaptosomal serotonin transport by the alpha 2-adrenoceptor agonist 5-bromo-N-[4,5-dihydro-1H-imidazol-2-yl]-6-quinoxalinamine (UK14304).
    Ansah TA; Ramamoorthy S; Montañez S; Daws LC; Blakely RD
    J Pharmacol Exp Ther; 2003 Jun; 305(3):956-65. PubMed ID: 12626658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and characterization of antidepressant-sensitive serotonin transporter proteins using site-specific antibodies.
    Qian Y; Melikian HE; Rye DB; Levey AI; Blakely RD
    J Neurosci; 1995 Feb; 15(2):1261-74. PubMed ID: 7869097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet serotonin transporter density and related parameters in endurance-trained and sedentary male subjects.
    Strachan AT; Maughan RJ
    Acta Physiol Scand; 1998 Jun; 163(2):165-71. PubMed ID: 9648635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet serotonin transporter (5HTt): physiological influences on kinetic characteristics in a large human population.
    Banović M; Bordukalo-Niksić T; Balija M; Cicin-Sain L; Jernej B
    Platelets; 2010; 21(6):429-38. PubMed ID: 20528260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.